CEO, Redhill Biopharma
Search every verified Guy Goldberg interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Guy Goldberg, Chief Business Officer of RedHill Biopharma, has presented the company's pipeline and commercial operations at several investor conferences between 2020 and 2025. At the 18th Annual European Life Sciences CEO Forum in May 2025, Goldberg discussed the company's development of opaganib for acute radiation syndrome (ARS) in collaboration with BARDA, noting that the study is underway and has generated positive data. He also highlighted the company's commercial product Talicia for H. pylori infection, stating that updated guidelines could drive revenue growth in coming quarters, and mentioned plans for an additional study of RHB-104 for Crohn's disease using endoscopic data. In earlier appearances, Goldberg described RedHill as a fully integrated specialty biopharmaceutical company with three FDA-approved commercial products and a late-stage pipeline. He stated that the company's annualized revenues exceeded $80 million as of Q1 2021 and that it had a cash position of over $90 million at that time. Goldberg characterized opaganib as a host-directed SK2 inhibitor with a dual mechanism of action being investigated for COVID-19, ARS, and oncology, and noted that the company was pursuing regulatory pathways including potential emergency use authorization applications. He also emphasized the public health importance of H. pylori eradication, citing its classification by the WHO as a carcinogen.
“If you can eradicate H. pylori you can reduce gastric cancer death by 75%, and that is very important because it really is a public health concern.”
“In the United States you can't really talk about commercial success without talking about managed care coverage. We've put a lot of effort and have over 100 million lives covered for TSIA, including seven out of ten on the commercial side and six out of ten on the government side.”
“As of the second quarter we have $71 million in cash, and our market cap (which of course changes on a regular basis) was as stated when we updated the presentation.”
“We think that we are the David versus Goliath here. We have a lot of promise with our drug and a very attractive profile as a novel once-daily oral pill.”
“Opaganib is the drug that we're formulating to try to treat severe covid-19 infection. It's an oral novel pill with a dual mechanism of action, both antiviral and anti-inflammatory, and that gives us several advantages. First, as a different mechanism of action from other drugs studied or approved, we will try to work...”
“Opaganib exerts its antiviral activity through targeting of a human host cell factor, so they act independently of the mutations to the viral spike protein. And by doing this, they're expected to be active against all these emerging variants that you hear about because they cast a wide net.”
“For a company of our size to have a fully integrated operation meeting three commercially approved, FDA approved products in addition to a very late stage and robust pipeline addressing many unmet medical needs is a unique opportunity. We're fast growing, revenue generated, we're focused on very exciting areas within t...”
“For a company of our size to have a fully integrated operation, three commercially approved FDA products and a very late-stage, robust pipeline addressing many unmet medical needs is a unique opportunity; our annualized revenues are over $80 million and we have a strong cash position of over $90 million as of the end o...”
“We believe that opaganib can overcome viral mutations because it exerts antiviral activity by targeting a human host factor, acting independently of viral mutations and is therefore expected to be active against emerging SARS‑CoV‑2 variants.”
“We've recently announced phase two data showing signals of efficacy for opaganib and are conducting a phase 2/3 study that we believe will be sufficient to support emergency use authorization applications.”
“H. pylori is classified by the WHO as a carcinogen on par with asbestos and smoking; if you get gastric cancer, it's almost certainly that you have it because you have an H. pylori infection.”
“We expect this continued revenue growth to bring us to cash flow break-even on a quarterly basis, possibly sometime next year.”
“If we're successful it really could revolutionize treatment protocols for this disease.”
“Our cash balance is 53 million dollars as of June 30th, so that's an important cash safety cushion that we have to be able to promote our commercial products and also advance our pipeline.”
“We're in the infectious disease space which is gaining momentum, a lot of awareness of the importance that it has both in public health and also in the financial markets today; they're also taking note.”
RedHill Biopharma Ltd. presentation by Guy Goldberg, Chief Business Officer at the 18th Annual European Life Sciences CEO Forum #Sachs_ELSF.
Guy Goldberg - Chief Business Officer, RedHill Biopharma (NASDAQ: RDHL)
Covid-19 has been the all-important topic in the last year - also on the stock exchange. RedHill Biopharma Ltd. from Israel is ...
Guy Goldberg, Chief Business Officer von RedHill Biopharma über zwei neuartige Produktkandidaten zur oralen Behandlung von COVID-19 auf der PLATOW EURO FINANCE Small Cap Konferenz.
Vivienne Parry talks to Guy Goldberg, CBO RedHill Biopharma is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases and infectious diseases. For more healthcare content, visit: https://www.edisongroup.com/our-conte...
Speciality pharma company RedHill Biopharma (Nasdaq: RDHL) primarily focuses on gastrointestinal and infectious diseases and promotes several products in the US. It also has a rapidly progressing COVID-19 R&D programme investigating a therapeutic drug. The commercial portfolio includes Movantik (opioid-induced constipation), Talicia (H. pylori eradication) and Aemcolo (travellers’ diarrhoea). The most advanced R&D assets are RHB-204 for Nontuberculous Mycobacteria infections, RHB-104 for Crohn’s disease and Bekinda for gastroenteritis and IBS-D. In this video, Guy Goldberg, chief business off…
RedHill Biopharma Ltd. (NASDAQ: RDHL) Full webcast at the SNN Network Virtual Conference on August 3-6, 2020. For more information about RedHill Biopharma, please visit: https://www.redhillbio.com/ The interview may contain forward looking statements about RedHill Biopharma Ltd. See RedHill Biopharma Ltd.'s periodic filings with the Securities and Exchange Commission for more complete information. About RedHill Biopharma Ltd. RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases. RedHill promotes the gastrointestinal d…
Sign in to search the full transcript archive, filter by topic, and access every quote from Guy Goldberg.
The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →